[
1. Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. 2021;11(123). DOI: 10.1038/s41408-021-00514-3824549434193815
]Open DOISearch in Google Scholar
[
2. Cicconi L, Testi AM, Montesinos P, Rego E, Zhu HH, Takahashi H, et al. Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. Blood Cancer J. 2021;11(10):14-7. DOI: 10.1038/s41408-021-00561-w852053234657125
]Open DOISearch in Google Scholar
[
3. Zhang X, Sun J, Yu W, Jin J. Current views on the genetic landscape and management of variant acute promyelocytic leukemia. Biomark Res. 2021;9(1):1-15. DOI: 10.1186/s40364-021-00284-x810113633957999
]Open DOISearch in Google Scholar
[
4. Baljevic M, Park JH, Stein E, Douer D, Altman JK, Tallman MS. Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet? Hematol Oncol Clin North Am. 2011;25(6):1215-33. DOI: 10.1016/j. hoc.2011.10.002
]Open DOISearch in Google Scholar
[
5. Stahl M, Tallman MS. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leuk Lymphoma. 2019;60(13):3107-15. DOI: 10.1080/10428194.2019.1613540747963331842650
]Open DOISearch in Google Scholar
[
6. Lehmann S, Ravn A, Carlsson L, Antunovic P, Deneberg S, Möllgrd L, et al. Continuing high early death rate in acute promyelocytic leukemia: A population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128-34. DOI: 10.1038/leu.2011.7821502956
]Open DOISearch in Google Scholar
[
7. Mi JQ, Li JM, Shen ZX, Chen SJ, Chen Z. How to manage acute promyelocytic leukemia. Leukemia. 2012;26(8):1743-51. DOI: 10.1038/leu.2012.5722422168
]Open DOISearch in Google Scholar
[
8. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302(1):1-12. DOI: 10.1016/j.ydbio.2006.08.02816989803
]Open DOISearch in Google Scholar
[
9. Ehtesham N, Sharifi M. From conventional therapy toward microRNA-based therapy in acute promyelocytic leukemia. Adv Biomed Res. 2016;5(1):187. DOI: 10.4103/2277-9175.190996515697528028527
]Open DOISearch in Google Scholar
[
10. Nervi C, Fazi F, Rosa A, Fatica A, Bozzoni I. Emerging role for microRNAs in acute promyelocytic leukemia. Curr Top Microbiol Immunol. 2007;313:73-84. DOI: 10.1007/978-3-540-34594-7_517217039
]Open DOISearch in Google Scholar
[
11. Liu Y, Cheng Z, Pang Y, Cui L, Qian T, Quan L, et al. Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia. J Hematol Oncol. 2019;12(1):1-20. DOI: 10.1186/s13045-019-0734-5653490131126316
]Open DOISearch in Google Scholar
[
12. Ismail I, Sulong S, Hassan R. MicroRNAs as Potential Biomarkers in Acute Promyelocytic Leukaemia. New J Sci. 2014;2014:1-6. DOI: 10.1155/2014/932342
]Open DOISearch in Google Scholar
[
13. Careccia S, Mainardi S, Pelosi A, Gurtner A, Diverio D, Riccioni R, et al. A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene. 2009;28(45):4034-40. DOI: 10.1038/onc.2009.25519749800
]Open DOISearch in Google Scholar
[
14. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):1-9. DOI: 10.1093/nar/gni178129299516314309
]Open DOISearch in Google Scholar
[
15. Lee K, Kang JH, Kim HM, Ahn J, Lim H, Lee JJ, et al. Direct electrophoretic microRNA preparation from clinical samples using nanofilter membrane. Nano Converg. 2020;7(1):1-11. DOI: 10.1186/s40580-019-0212-3695538531930443
]Open DOISearch in Google Scholar
[
16. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101-8. DOI: 10.1038/nprot.2008.7318546601
]Open DOISearch in Google Scholar
[
17. Scaglioni PP, Pandolfi PP. The theory of APL revisited. Curr Top Microbiol Immunol. 2007;313:85-100. DOI: 10.1007/978-3-540-34594-7_617217040
]Open DOISearch in Google Scholar
[
18. Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, et al. miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer. Mol Oncol. 2019;13(10):2278-96. DOI: 10.1002/1878-0261.12561676378031402562
]Open DOISearch in Google Scholar
[
19. Hummel R, Wang T, Watson DI, Michael MZ, Van Der Hoek M, Haier J, et al. Chemotherapy-induced modification of microRNA expression in esophageal cancer. Oncol Rep. 2011;26(4):1011-7. DOI: 10.3892/or.2011.138121743970
]Open DOISearch in Google Scholar
[
20. Rooda I, Hensen K, Kaselt B, Kasvandik S, Pook M, Kurg A, et al. Target prediction and validation of microRNAs expressed from FSHR and aromatase genes in human ovarian granulosa cells. Sci Rep. 2020;10(1):1-13. DOI: 10.1038/s41598-020-59186-x701077432042028
]Open DOISearch in Google Scholar
[
21. Riolo G, Cantara S, Marzocchi C, Ricci C. miRNA targets: From prediction tools to experimental validation. Methods Protoc. 2021;4(1):1-20. DOI: 10.3390/mps4010001783903833374478
]Open DOISearch in Google Scholar
[
22. Svec D, Tichopad A, Novosadova V, Pfaffl MW, Kubista M. How good is a PCR efficiency estimate: Recommendations for precise and robust qPCR efficiency assessments. Biomol Detect Quantif. 2015;3:9-16. DOI: 10.1016/j.bdq.2015.01.005482221627077029
]Open DOISearch in Google Scholar
